Interestingly, ruxolitinib did not have any effect on TNF-α production and surprisingly seemed to increase soluble IL-17A production by SLE-PBMCs in a dose-dependent manner whereas UCB-Tregs led to a significant reduction of IL-17A. Here, TNF is linked to systemic lupus erythematosus.